Molecular subgrouping of gliomas using mutations in isocitrate dehydrogenase (IDH) 1/2, TERT promoter, and ATRX and codeletion of 1p/19q as biomarkers stratifies patients into distinct groups that are more prognostically assessed compared with conventional histological classifications [1], [3], [4], [5]. This evidence concerns the gene ATRX and glioma.